Real-World Pharmacokinetic/Pharmacodynamic Study of Eravacycline in Critically III Patients

Launched by SICHUAN PROVINCIAL PEOPLE'S HOSPITAL · Oct 30, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a medication called Eravacycline, which is used to treat serious bacterial infections in critically ill patients. The goal is to see how well Eravacycline works and to understand how the body processes this drug, which is important for ensuring it is effective and safe for patients. The study aims to help doctors better use Eravacycline, especially for patients who have not improved with other treatments.

To participate in this trial, you must be an adult aged 18 to 75 who has not responded to initial treatments for a bacterial infection. You should be able to take Eravacycline for at least three days and agree to sign a consent form that explains the study. However, if you have certain conditions, like a urinary tract infection or a serious allergy to similar antibiotics, you may not be eligible. If you join the study, you can expect to receive the medication and be monitored closely by the medical team to ensure your safety and to gather important information about how well the treatment works. This study is not yet recruiting participants, so you will need to wait for it to begin before you can apply.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult male or female aged 18-75 years
• • Not respond to initial empirical treatment, treatment time to reach Eravacycline steady-state concentration
• • Empirical antimicrobial treatment is ineffective
• • Eravacycline application for ≥ 3 days
• • Understand and sign informed consent
• Exclusion Criteria:
• • Urinary tract infection
• • Allergic to Eravacycline, Tigecycline antibiotics or any excipients or have previously experienced serious adverse reactions
• • Any unstable or potentially endangering the safety of the subject and their compliance with the study as judged by the investigator; comorbidities or social circumstances that can make the subject unable to follow the study plan or even endanger the safety of the patient
• • Patients expected to survive for no longer than 48h.